# Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients

> **NCT02058680** · PHASE1 · UNKNOWN · sponsor: **OncBioMune Pharmaceuticals** · enrollment: 48 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** PSA/IL-2/GM-CSF

## Key facts

- **NCT ID:** NCT02058680
- **Lead sponsor:** OncBioMune Pharmaceuticals
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-04
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2018-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02058680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02058680, "Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02058680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*